• Explore /
  • Poster
  • / HELIX-ICC: An-open label phase II trial of induction systemic mFOLFIRINOX followed by concurrent hepatic arterial infusion of floxuridine and systemic mFOLFIRI for unresectable intrahepatic cholangiocarcinoma.

HELIX-ICC: An-open label phase II trial of induction systemic mFOLFIRINOX followed by concurrent hepatic arterial infusion of floxuridine and systemic mFOLFIRI for unresectable intrahepatic cholangiocarcinoma.

Abstract Poster

Authors

null

Brett S Walker

Oregon Health & Science University, Portland, OR

Brett S Walker , Adel Kardosh , Robert Eil , Melissa Wong , Alice Fung , Jonathan Brody , Sudarshan Anand , Christopher L. Corless , Lissi Hansen , Susan Rosenkranz , Byung Park , Emerson Yu-sheng Chen , Anna Jackson , Johnson Vo , Anne Fahlman , Flavio G. Rocha , Charles D. Lopez , Shaun Goodyear , Skye C. Mayo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04251715

DOI

10.1200/JCO.2022.40.4_suppl.TPS500

Abstract #

TPS500

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Andrea Cercek

First Author: Gustavo Dos Santos Fernandes

First Author: Patrick Grierson

First Author: Chigusa Morizane